However, the AZ304 and Cetuximab combination reversed EGFR activation associated with AZ304, and resulted in stronger anti-tumour activity in vitro and in vivo, in RAS wild type CRC cells irrespective of BRAF genetic status. This evidence concerns the gene BRAF and neoplasm.